Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.

Takaaki IshidaShuzo YoshidaYouhei FujikiKenichiro HataTakuya KotaniTohru Takeuchi

Published in: Archives of osteoporosis (2021)

In conclusion, denosumab is a potential treatment for GIOP in rheumatic diseases, especially in patients refractory to previous therapy, including bisphosphonate therapy.

Keyphrases

bone mineral density
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
postmenopausal women
peritoneal dialysis
prognostic factors
stem cells
giant cell
high glucose
bone marrow
climate change
cell therapy
human health
replacement therapy